Identification

Name
Biperiden
Accession Number
DB00810  (APRD00725)
Type
Small Molecule
Groups
Approved, Investigational
Description

A muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine. [PubChem]

Structure
Thumb
Synonyms
  • 1-Bicyclo[2.2.1]hept-5-en-2-yl-1-phenyl-3-piperidin-1-yl-propan-1-ol
  • alpha-5-Norbornen-2-yl-alpha-phenyl-1-piperidinepropanol
  • alpha-Bicyclo[2.2.1]hept-5-en-2-yl-alpha-phenyl-1-piperidinepropanol
  • Beperiden
  • Biperidene
  • Biperideno
  • Biperidenum
Product Ingredients
IngredientUNIICASInChI Key
Biperiden hydrochlorideK35N76CUHF1235-82-1RDNLAULGBSQZMP-UHFFFAOYSA-N
Biperiden lactate09TD6C51477085-45-2GLPUBCPQWZZFNJ-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Akineton Tab 2mgTablet2 mgOralAbbott1985-12-312007-07-31Canada
International/Other Brands
Akineton (Abbott) / Bilino (Winston) / Ipsatol (Orion)
Categories
UNII
0FRP6G56LD
CAS number
514-65-8
Weight
Average: 311.4611
Monoisotopic: 311.224914555
Chemical Formula
C21H29NO
InChI Key
YSXKPIUOCJLQIE-UHFFFAOYSA-N
InChI
InChI=1S/C21H29NO/c23-21(19-7-3-1-4-8-19,11-14-22-12-5-2-6-13-22)20-16-17-9-10-18(20)15-17/h1,3-4,7-10,17-18,20,23H,2,5-6,11-16H2
IUPAC Name
1-{bicyclo[2.2.1]hept-5-en-2-yl}-1-phenyl-3-(piperidin-1-yl)propan-1-ol
SMILES
OC(CCN1CCCCC1)(C1CC2CC1C=C2)C1=CC=CC=C1

Pharmacology

Indication

For use as an adjunct in the therapy of all forms of parkinsonism and control of extrapyramidal disorders secondary to neuroleptic drug therapy.

Structured Indications
Not Available
Pharmacodynamics

Biperiden is a weak peripheral anticholinergic agent. It has, therefore, some antisecretory, antispasmodic and mydriatic effects. In addition, biperiden possesses nicotinolytic activity. The parenteral form of biperiden is an effective and reliable agent for the treatment of acute episodes of extrapyramidal disturbances sometimes seen during treatment with neuroleptic agents. Akathisia, akinesia, dyskinetic tremors, rigor, oculogyric crisis, spasmodic torticollis, and profuse sweating are markedly reduced or eliminated. With parenteral biperiden, these drug-induced disturbances are rapidly brought under control.

Mechanism of action

Parkinsonism is thought to result from an imbalance between the excitatory (cholinergic) and inhibitory (dopaminergic) systems in the corpus striatum. The mechanism of action of centrally active anticholinergic drugs such as biperiden is considered to relate to competitive antagonism of acetylcholine at cholinergic receptors in the corpus striatum, which then restores the balance.

TargetActionsOrganism
AMuscarinic acetylcholine receptor M1
antagonist
Human
ANeuronal acetylcholine receptor subunit alpha-2
antagonist
Human
Absorption

87% bioavailability

Volume of distribution
Not Available
Protein binding

60%

Metabolism

The metabolism of biperiden is not completely understood, but does involve hydroxylation.

Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

LD50=760 mg/kg (Orally in rats). Signs of overdose include dilated and sluggish pupils, warm, dry skin, facial flushing, decreased secretions of the mouth, pharynx, nose, and bronchi, foul-smelling breath, elevated temperature, tachycardia, cardiac arrhythmias, decreased bowel sounds, urinary retention, delirium, disorientation, anxiety, hallucinations, illusions, confusion, incoherence, agitation, hyperactivity, ataxia, loss of memory, paranoia, combativeness, and seizures.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe therapeutic efficacy of Biperiden can be decreased when used in combination with 1,10-Phenanthroline.Experimental
AclidiniumAclidinium may increase the anticholinergic activities of Biperiden.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Biperiden.Approved
AlcuroniumThe risk or severity of adverse effects can be increased when Biperiden is combined with Alcuronium.Experimental
AlfentanilThe risk or severity of adverse effects can be increased when Biperiden is combined with Alfentanil.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Biperiden is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Biperiden is combined with Alphaprodine.Illicit
AmbenoniumThe therapeutic efficacy of Biperiden can be decreased when used in combination with Ambenonium.Approved
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Biperiden is combined with Anisotropine Methylbromide.Approved
AtracuriumThe risk or severity of adverse effects can be increased when Biperiden is combined with Atracurium.Experimental, Investigational
Atracurium besylateThe risk or severity of adverse effects can be increased when Biperiden is combined with Atracurium besylate.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Biperiden.Approved, Vet Approved
BenactyzineThe risk or severity of adverse effects can be increased when Biperiden is combined with Benactyzine.Withdrawn
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Biperiden.Approved
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Biperiden.Approved
BezitramideThe risk or severity of adverse effects can be increased when Biperiden is combined with Bezitramide.Experimental, Illicit, Withdrawn
BornaprineThe risk or severity of adverse effects can be increased when Biperiden is combined with Bornaprine.Experimental
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Biperiden.Approved
Botulinum Toxin Type ABiperiden may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BBiperiden may increase the anticholinergic activities of Botulinum Toxin Type B.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Biperiden.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Biperiden is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Biperiden is combined with Butorphanol.Approved, Illicit, Vet Approved
CarfentanilThe risk or severity of adverse effects can be increased when Biperiden is combined with Carfentanil.Illicit, Investigational, Vet Approved
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Biperiden.Approved, Vet Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Biperiden is combined with Chlorphenoxamine.Withdrawn
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Biperiden.Approved
CimetropiumBiperiden may increase the anticholinergic activities of Cimetropium.Experimental, Investigational
CodeineThe risk or severity of adverse effects can be increased when Biperiden is combined with Codeine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Biperiden.Approved
CoumaphosThe therapeutic efficacy of Biperiden can be decreased when used in combination with Coumaphos.Vet Approved
CyclopenthiazideThe serum concentration of Cyclopenthiazide can be increased when it is combined with Biperiden.Experimental
CyclopentolateThe risk or severity of adverse effects can be increased when Biperiden is combined with Cyclopentolate.Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Biperiden.Approved
DarifenacinThe risk or severity of adverse effects can be increased when Biperiden is combined with Darifenacin.Approved, Investigational
DecamethoniumThe therapeutic efficacy of Biperiden can be decreased when used in combination with Decamethonium.Approved
DemecariumThe therapeutic efficacy of Biperiden can be decreased when used in combination with Demecarium.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Biperiden is combined with Desloratadine.Approved, Investigational
DexetimideThe risk or severity of adverse effects can be increased when Biperiden is combined with Dexetimide.Withdrawn
DextromoramideThe risk or severity of adverse effects can be increased when Biperiden is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Biperiden is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Biperiden is combined with Dezocine.Approved, Investigational
DichlorvosThe therapeutic efficacy of Biperiden can be decreased when used in combination with Dichlorvos.Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Biperiden is combined with Dicyclomine.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Biperiden is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Biperiden is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Biperiden is combined with Dihydromorphine.Experimental, Illicit
DiphenoxylateThe risk or severity of adverse effects can be increased when Biperiden is combined with Diphenoxylate.Approved, Illicit
DistigmineThe therapeutic efficacy of Biperiden can be decreased when used in combination with Distigmine.Experimental
DonepezilThe therapeutic efficacy of Biperiden can be decreased when used in combination with Donepezil.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Biperiden.Approved, Investigational
DPDPEThe risk or severity of adverse effects can be increased when Biperiden is combined with DPDPE.Experimental
DronabinolBiperiden may increase the tachycardic activities of Dronabinol.Approved, Illicit
EchothiophateThe therapeutic efficacy of Biperiden can be decreased when used in combination with Echothiophate.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Biperiden.Approved
EdrophoniumThe therapeutic efficacy of Biperiden can be decreased when used in combination with Edrophonium.Approved
EluxadolineBiperiden may increase the constipating activities of Eluxadoline.Approved
EmeproniumThe risk or severity of adverse effects can be increased when Biperiden is combined with Emepronium.Experimental
EtanautineThe risk or severity of adverse effects can be increased when Biperiden is combined with Etanautine.Experimental
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Biperiden.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Biperiden is combined with Ethylmorphine.Approved, Illicit
EtorphineThe risk or severity of adverse effects can be increased when Biperiden is combined with Etorphine.Illicit, Vet Approved
EtybenzatropineThe risk or severity of adverse effects can be increased when Biperiden is combined with Etybenzatropine.Experimental
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Biperiden.Approved
FentanylThe risk or severity of adverse effects can be increased when Biperiden is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionThe therapeutic efficacy of Biperiden can be decreased when used in combination with Fenthion.Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Biperiden.Approved
GalantamineThe therapeutic efficacy of Biperiden can be decreased when used in combination with Galantamine.Approved
GallamineThe risk or severity of adverse effects can be increased when Biperiden is combined with Gallamine.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Biperiden is combined with Gallamine Triethiodide.Approved
Glucagon recombinantThe risk or severity of adverse effects can be increased when Biperiden is combined with Glucagon recombinant.Approved
GlycopyrroniumBiperiden may increase the anticholinergic activities of Glycopyrronium.Approved, Investigational, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Biperiden is combined with Heroin.Approved, Illicit, Investigational
HexamethoniumThe risk or severity of adverse effects can be increased when Biperiden is combined with Hexamethonium.Experimental
HomatropineThe risk or severity of adverse effects can be increased when Biperiden is combined with Homatropine.Approved
Huperzine AThe therapeutic efficacy of Biperiden can be decreased when used in combination with Huperzine A.Investigational
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Biperiden.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Biperiden is combined with Hydrocodone.Approved, Illicit
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Biperiden.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Biperiden is combined with Hydromorphone.Approved, Illicit
HyoscyamineThe risk or severity of adverse effects can be increased when Biperiden is combined with Hyoscyamine.Approved
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Biperiden.Approved
IpidacrineThe therapeutic efficacy of Biperiden can be decreased when used in combination with Ipidacrine.Experimental
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Biperiden.Approved
IsoflurophateThe therapeutic efficacy of Biperiden can be decreased when used in combination with Isoflurophate.Approved, Investigational, Withdrawn
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Biperiden.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Biperiden is combined with Ketobemidone.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Biperiden.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Biperiden is combined with Levomethadyl Acetate.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Biperiden is combined with Levorphanol.Approved
LofentanilThe risk or severity of adverse effects can be increased when Biperiden is combined with Lofentanil.Illicit
MalathionThe therapeutic efficacy of Biperiden can be decreased when used in combination with Malathion.Approved, Investigational
MazaticolThe risk or severity of adverse effects can be increased when Biperiden is combined with Mazaticol.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Biperiden is combined with Mecamylamine.Approved
MefloquineThe therapeutic efficacy of Biperiden can be decreased when used in combination with Mefloquine.Approved
MemantineThe therapeutic efficacy of Biperiden can be decreased when used in combination with Memantine.Approved, Investigational
MeptazinolThe risk or severity of adverse effects can be increased when Biperiden is combined with Meptazinol.Experimental
MethadoneThe risk or severity of adverse effects can be increased when Biperiden is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Biperiden is combined with Methadyl Acetate.Approved, Illicit
Methanesulfonyl FluorideThe therapeutic efficacy of Biperiden can be decreased when used in combination with Methanesulfonyl Fluoride.Investigational
MethanthelineThe risk or severity of adverse effects can be increased when Biperiden is combined with Methantheline.Approved, Investigational
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Biperiden.Approved
Methylscopolamine bromideThe risk or severity of adverse effects can be increased when Biperiden is combined with Methylscopolamine bromide.Approved
MetixeneThe risk or severity of adverse effects can be increased when Biperiden is combined with Metixene.Approved
MetoclopramideThe therapeutic efficacy of Biperiden can be decreased when used in combination with Metoclopramide.Approved, Investigational
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Biperiden.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Biperiden.Approved, Investigational
MianserinMianserin may increase the anticholinergic activities of Biperiden.Approved, Investigational
MinaprineThe therapeutic efficacy of Biperiden can be decreased when used in combination with Minaprine.Approved
MirabegronThe risk or severity of adverse effects can be increased when Biperiden is combined with Mirabegron.Approved
MorphineThe risk or severity of adverse effects can be increased when Biperiden is combined with Morphine.Approved, Investigational
NabiloneBiperiden may increase the tachycardic activities of Nabilone.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Biperiden is combined with Nalbuphine.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Biperiden.Approved
NeostigmineThe therapeutic efficacy of Biperiden can be decreased when used in combination with Neostigmine.Approved, Vet Approved
NicomorphineThe risk or severity of adverse effects can be increased when Biperiden is combined with Nicomorphine.Experimental
NormethadoneThe risk or severity of adverse effects can be increased when Biperiden is combined with Normethadone.Approved, Illicit
OpiumThe risk or severity of adverse effects can be increased when Biperiden is combined with Opium.Approved, Illicit
OrphenadrineThe risk or severity of adverse effects can be increased when Biperiden is combined with Orphenadrine.Approved
OtiloniumThe risk or severity of adverse effects can be increased when Biperiden is combined with Otilonium.Experimental, Investigational
OxitropiumThe risk or severity of adverse effects can be increased when Biperiden is combined with Oxitropium.Investigational
OxybutyninThe risk or severity of adverse effects can be increased when Biperiden is combined with Oxybutynin.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Biperiden is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Biperiden is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Biperiden is combined with Oxyphenonium.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Biperiden is combined with Pancuronium.Approved
ParaoxonThe therapeutic efficacy of Biperiden can be decreased when used in combination with Paraoxon.Experimental
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Biperiden.Approved
PentazocineThe risk or severity of adverse effects can be increased when Biperiden is combined with Pentazocine.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Biperiden is combined with Pentolinium.Approved
PethidineThe risk or severity of adverse effects can be increased when Biperiden is combined with Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Biperiden is combined with Phenazocine.Experimental
PhenglutarimideThe risk or severity of adverse effects can be increased when Biperiden is combined with Phenglutarimide.Experimental
PhenoperidineThe risk or severity of adverse effects can be increased when Biperiden is combined with Phenoperidine.Experimental
PhysostigmineThe therapeutic efficacy of Biperiden can be decreased when used in combination with Physostigmine.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Biperiden is combined with Pipecuronium.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Biperiden is combined with Pirenzepine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Biperiden is combined with Piritramide.Investigational
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Biperiden.Approved
Potassium ChlorideBiperiden may increase the ulcerogenic activities of Potassium Chloride.Approved, Withdrawn
PramlintidePramlintide may increase the anticholinergic activities of Biperiden.Approved, Investigational
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Biperiden.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Biperiden is combined with Propantheline.Approved
PropiverineThe risk or severity of adverse effects can be increased when Biperiden is combined with Propiverine.Approved, Investigational
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Biperiden.Approved
PyridostigmineThe therapeutic efficacy of Biperiden can be decreased when used in combination with Pyridostigmine.Approved
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Biperiden.Approved
QuinidineThe risk or severity of adverse effects can be increased when Biperiden is combined with Quinidine.Approved
RamosetronBiperiden may increase the constipating activities of Ramosetron.Approved, Investigational
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Biperiden.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Biperiden is combined with Remifentanil.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Biperiden.Approved, Investigational
RivastigmineThe therapeutic efficacy of Biperiden can be decreased when used in combination with Rivastigmine.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Biperiden.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Biperiden is combined with Scopolamine butylbromide.Approved, Vet Approved
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Biperiden.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Biperiden.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Biperiden is combined with Solifenacin.Approved
SufentanilThe risk or severity of adverse effects can be increased when Biperiden is combined with Sufentanil.Approved, Investigational
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Biperiden.Approved, Investigational
TacrineThe therapeutic efficacy of Biperiden can be decreased when used in combination with Tacrine.Investigational, Withdrawn
TapentadolThe risk or severity of adverse effects can be increased when Biperiden is combined with Tapentadol.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Biperiden.Approved, Withdrawn
TilidineThe risk or severity of adverse effects can be increased when Biperiden is combined with Tilidine.Experimental
TiotropiumBiperiden may increase the anticholinergic activities of Tiotropium.Approved
TolterodineThe risk or severity of adverse effects can be increased when Biperiden is combined with Tolterodine.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Biperiden is combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Biperiden.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Biperiden is combined with Tramadol.Approved, Investigational
TrichlorfonThe therapeutic efficacy of Biperiden can be decreased when used in combination with Trichlorfon.Vet Approved
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Biperiden.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Biperiden.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Biperiden is combined with Trimethaphan.Approved, Investigational
TropatepineThe risk or severity of adverse effects can be increased when Biperiden is combined with Tropatepine.Experimental
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Biperiden.Approved
TrospiumThe risk or severity of adverse effects can be increased when Biperiden is combined with Trospium.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Biperiden is combined with Tubocurarine.Approved
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Biperiden.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Biperiden is combined with Vecuronium.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Biperiden.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take with food.

References

Synthesis Reference

Peter Klein, "Method for the production of biperiden II." U.S. Patent US20040152899, issued August 05, 2004.

US20040152899
General References
  1. Nishiyama K, Mizuno T, Sakuta M, Kurisaki H: Chronic dementia in Parkinson's disease treated by anticholinergic agents. Neuropsychological and neuroradiological examination. Adv Neurol. 1993;60:479-83. [PubMed:8420174]
External Links
Human Metabolome Database
HMDB14948
KEGG Drug
D00779
KEGG Compound
C07941
PubChem Compound
2381
PubChem Substance
46508325
ChemSpider
2289
BindingDB
50240680
ChEBI
3112
ChEMBL
CHEMBL1101
Therapeutic Targets Database
DAP001125
PharmGKB
PA448626
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Biperiden
ATC Codes
N04AA02 — Biperiden

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2, 3CompletedTreatmentCocaine Related Disorders1
3CompletedTreatmentCrack Cocaine Dependence / Dependence, Cocaine1
3RecruitingTreatmentTraumatic Brain Injury (TBI)1
3TerminatedTreatmentAnxiety Disorders / Dementias / Depression / Psychosomatic Disorders / Schizophrenic Disorders1
4Unknown StatusTreatmentDependence, Cocaine1

Pharmacoeconomics

Manufacturers
  • Abbott laboratories
Packagers
Dosage forms
FormRouteStrength
TabletOral2 mg
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)114 °CPhysProp
water solubility25.1 mg/LNot Available
logP4.25SANGSTER (1993)
Predicted Properties
PropertyValueSource
Water Solubility0.00426 mg/mLALOGPS
logP4.28ALOGPS
logP3.54ChemAxon
logS-4.9ALOGPS
pKa (Strongest Acidic)13.82ChemAxon
pKa (Strongest Basic)9.3ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area23.47 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity97.02 m3·mol-1ChemAxon
Polarizability36.74 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9669
Blood Brain Barrier+0.9808
Caco-2 permeable+0.6422
P-glycoprotein substrateSubstrate0.7189
P-glycoprotein inhibitor IInhibitor0.6211
P-glycoprotein inhibitor IINon-inhibitor0.8284
Renal organic cation transporterInhibitor0.7592
CYP450 2C9 substrateNon-substrate0.8119
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.5193
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9084
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.9056
CYP450 3A4 inhibitorNon-inhibitor0.9041
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9558
Ames testNon AMES toxic0.8194
CarcinogenicityNon-carcinogens0.9309
BiodegradationNot ready biodegradable0.8756
Rat acute toxicity2.6495 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.6982
hERG inhibition (predictor II)Non-inhibitor0.6332
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (7.72 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Mass Spectrum (Electron Ionization)MSsplash10-0002-9000000000-92eb93b999cf7f5ec519
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as aralkylamines. These are alkylamines in which the alkyl group is substituted at one carbon atom by an aromatic hydrocarbyl group.
Kingdom
Organic compounds
Super Class
Organic nitrogen compounds
Class
Organonitrogen compounds
Sub Class
Amines
Direct Parent
Aralkylamines
Alternative Parents
Piperidines / Benzene and substituted derivatives / Tertiary alcohols / 1,3-aminoalcohols / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives / Aromatic alcohols
Substituents
Aralkylamine / Monocyclic benzene moiety / Piperidine / Benzenoid / 1,3-aminoalcohol / Tertiary alcohol / Tertiary amine / Tertiary aliphatic amine / Azacycle / Organoheterocyclic compound
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
piperidines, tertiary alcohol, tertiary amino compound (CHEBI:3112)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM1
Uniprot ID
P11229
Uniprot Name
Muscarinic acetylcholine receptor M1
Molecular Weight
51420.375 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Hosoi R, Kobayashi K, Watanabe Y, Inoue O: Evaluation of in vivo binding properties of 3H-NMPB and 3H-QNB in mouse brain. J Neural Transm (Vienna). 1999;106(7-8):583-92. [PubMed:10907719]
  4. Pehl C, Wendl B, Kaess H, Pfeiffer A: Effects of two anticholinergic drugs, trospium chloride and biperiden, on motility and evoked potentials of the oesophagus. Aliment Pharmacol Ther. 1998 Oct;12(10):979-84. [PubMed:9798802]
  5. Eltze M: Multiple mechanisms of action: the pharmacological profile of budipine. J Neural Transm Suppl. 1999;56:83-105. [PubMed:10370904]
  6. Eltze M, Galvan M: Involvement of muscarinic M2 and M3, but not of M1 and M4 receptors in vagally stimulated contractions of rabbit bronchus/trachea. Pulm Pharmacol. 1994 Apr;7(2):109-20. [PubMed:8081071]
  7. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Drug binding
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name
CHRNA2
Uniprot ID
Q15822
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-2
Molecular Weight
59764.82 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. [PubMed:12438524]

Drug created on June 13, 2005 07:24 / Updated on November 07, 2017 01:43